Symposium on

Therapeutic Applications of Stem Cells:

Current and Future Prospects

Level 10, Hibiscus Room, DoubleTree by Hilton KL

Normal Price

MYR150
  • Limited Seat Available
Days
Hours
Minutes
Seconds

Event

Itinerary

09:00 am – 09:30 am

Registration

09:30 am – 09:40 am

Welcome remarks by ALPS Group CEO

Dr. Tham Seng Kong

CHIEF EXECUTIVE OFFICER (CEO), ALPS GROUP

Dr. THAM earned his Bachelor of Medicine from Xiamen University, Doctor of Medicine (MD) Integrated Chinese Medicine . . .
09:40 am – 10:00 am

Introduction to ALPS; cGMP Stem Cell & Genomic Facilities

Ms. Amanda Low

VICE PRESIDENT, BUSINESS DEVELOPMENT, ALPS Group

10:00 am – 11:00 am

1st Session: Stem Cells in Personalized Medicine

Prof. Manickam Ravichandran

CHIEF SCIENTIFIC OFFICER (CSO), ALPS GROUP

Prof M. Ravichandran obtained his M.Sc. Medical Microbiology from Christian Medical College, Vellore, India, and gained his PhD in Biotechnology . . .

11:00 am – 11:15 am

Tea Break

11:15 am – 12:15 pm

2nd Session: Stem Cells and Diabetes: Preclinical
Proof of Concept Studies

Prof. Ding Ke Xiang

CHIEF SCIENTIST, ALPS Group & Southern Medical University of China

Dr. Tham Seng Kong

CHIEF EXECUTIVE OFFICER (CEO), ALPS Group

Ding Kexiang is currently a professor and chief expert in research topics at the School of Public Health and Tropical Medicine at the Southern Medical University of China . .  .

12:15 pm – 01:15 pm

3rd Session: Induced Pluripotent Stem Cells (iPSCs) for Myocardial Regeneration

Assoc. Prof. Tan Jun Jie

CONSULTANT, CELESTIALAB, AMDI, USM

Dr. Tan Jun Jie graduated from Universiti Putra Malaysia in 2007 majoring in Biomedical Sciences (First class) and obtained his . . .

01:15 pm – 02:00 pm

Buffet Lunch at “Makan Kitchen”

02:00 pm – 03:00 pm

4th Session: Recent Advances in Stem Cells & Ophthalmology

Prof. Wei Li

DIRECTOR, EYE INSTITUTE of Xiamen University

Amniotic membrane related tissue engineering: Amniotic membrane has been widely applied in ophthalmology and other tissue engineering areas in . . .

03:00 pm – 04:00 pm

5th Session: Clinician's Perspective on Stem Cell Therapy

Dr. Chua Kok Seng

ANAESTHESIOLOGY & CRITICAL CARE, Gleneagles Kuala Lumpur

Dr Chua Kok Seng has been involved in the Science of Stem Cell Biology and Therapeutics since 2000. In 2006, he was invited to be a board member of Stem Cell Berhad . . .

04:00 pm – 04:15 pm

Tea Break

04:15 pm – 05:15 pm

6th Session: Booth Tour & Demonstration of Stem Cells & Natural Killer (NK) Cell Cultures

05:15 pm – 06:00 pm

Networking Session

Early Bird

(First 10 pax)

Symposium on Therapeutic Application of Stem Cells: Current and Future Prospects

RM10

Program Fee

Symposium on Therapeutic Application of Stem Cells: Current and Future Prospects

RM150

Location

DoubleTree by Hilton Kuala Lumpur, The Intermark, 348, Jln Tun Razak, Kampung Datuk Keramat, 50400 Kuala Lumpur, Federal Territory of Kuala Lumpur

© COPYRIGHT 2023 POWERED BY Célebre Pro Medic Sdn Bhd

DR. THAM SENG KONG

CHIEF EXECUTIVE OFFICER (CEO),
ALPS GROUP

PHD. , MD (PRC)

Biography:

Dr. THAM earned his Bachelor of Medicine from Xiamen University, Doctor of Medicine (MD) Integrated Chinese Medicine & Western Clinical Medicine (Oncology) from Guangzhou University of Chinese Medicine (GUCM) and Doctor of Medicine (PHD) in Biomedical Engineering.

He is involved in ongoing extensive research on anti-aging cellular therapy since 2006. He works very closely with his Swiss and Asian counterparts in advancing the human understanding of cellular therapy and is eager to share his experiences in this field.

He also actively participates in cancer research. One of his important scientific breakthroughs is the discovery of penetrating tyrosinase inhibitor to reduce the production of melanin for skin beauty and whitening. He also described in his recent publication on the successful construction of retroviral transfection system that could be developed as a means of gene therapy for hepatic carcinoma.

Dr. Tham as Group Chief Executive Officer and Group Chief Research Scientist is the main personality leading and driving the ALPS Group to greater heights towards recognition as a global biotechnology company serving humanity.

PROF. MANICKAM RAVICHANDRAN

CHIEF SCIENTIFIC OFFICER (CSO), ALPS Group

Biography:

Prof M. Ravichandran obtained his M.Sc. Medical Microbiology from Christian Medical College, Vellore, India, and gained his PhD in Biotechnology from Anna University, Chennai, India. His research interests are Human lymphatic filariasis, genetically engineered cholera vaccine and formulation, Covid-19 vaccine and drug development, molecular diagnostics and phage therapy. He has 80 publications in international journals with 2027 citations and an h-index of 25. He has supervised 55 MSc/PhD students and examined 65 postgraduate students locally and internationally. He has filed 14 patents. On product development, he successfully technology transferred EZDNA Amp diagnostic technology and commercialised three products on diagnostics. He has written over 21 articles in the press, and he is a New Strait Times (NST) columnist.

Previously Prof Ravi was the former Chief Executive and Vice-Chancellor of AIMST University, Malaysia. He was also the Chairman of Covid-19 Task force at AIMST University. He holds director positions at Vax Biotech Sdn. Bhd., Malaysia, which is a spin-off company of his cholera vaccine patent. He has been awarded 50 national and international awards for academic and research excellence, including Ideas Inventions New Products – (iENA), Nuremberg Germany; International Exhibition of Inventions: New Technologies and Products, Geneva and National Innovation Award, Malaysia. He was an associate member and the committee member on ‘TOP RESEARCH SCIENTISTS MALAYSIA’ (TRSM) of the Academy of Sciences Malaysia (ASM).

Prof. DING KEXIANG

CHIEF SCIENTIST, ALPS Group & Southern Medical University of China

Biography:

Ding Kexiang is currently a professor and chief expert in research topics at the School of Public Health and Tropical Medicine at the Southern Medical University of China. He previously served as director of the Molecular Medicine Laboratory at ABTRI, as well as a visiting doctoral tutor at the Basic Medical College of Bethune Medical University and a member of the echelon of doctoral tutors at the Institute of Integrated Chinese and Western Medicine at Sun Yat-sen Medical University. In addition, Dr. Kexiang has held visiting professor positions at the University of Virginia and Harvard University, and served as a postdoctoral research scholar at the Center for Cell and Gene Therapy at Baylor College of Medicine.

Prof. Ding received several prestigious awards in 1992, including “National Young and Middle Aged Scientific and Technological Expert with Outstanding Contribution” and “Special Government Allowance Expert.” He also earned the “First China Young Scientist Entrepreneurship Award,” the “Bioengineering Expert” award, and was recognized as a research professor by various institutions. In addition, he was named one of the “Top Ten Outstanding Young People in Guangzhou” and awarded “Top Ten Rookie of Science and Technology.”

In 2006, he was appointed lifelong chief scientist by the International Nutrition and Hygiene Research Institute in Toronto, Canada, and lifelong honorary chairman by the Canadian International Institute of Health Sciences and Technology. He was also awarded lifelong honorary chairman by the North American Beauty and Health Association in Vancouver, Canada.

Additionally, he serves as a visiting professor and academic advisor at Tai E College of Traditional Chinese Medicine in Quebec, Canada. He is chairman of the expert committee of the Organizing Committee of the Southeast Asian Regional Medical Aesthetic Conference, a counselor and expert committee member of CIDESIC SECTION in Hong Kong, and academic adviser of Taiwan Free Radical Biomedical Research Center.

He also holds various positions including vice chairman of China Anti-aging Science and Technology Society, expert committee member of China Health Care Association, and vice chairman of China Beauty Industry Association. He is on the editorial board of several scientific journals including Free Radical Biomedicine, Chinese Journal of Gerontology, Practical Geriatrics, Modern Geriatrics, Microcirculation, and Chinese Cosmetics Magazine. He also serves as the editor-in-chief or deputy editor-in-chief of other Chinese and international scientific journals.

Assoc. Prof. TAN JUN JIE

CONSULTANT, CELESTIALAB, AMDI, USM

BSC IN BIOMEDICAL SCIENCE (UPM), DPHIL (OXFORD), POSTDOC (HARVARD)

Biography:

Dr. Tan Jun Jie graduated from Universiti Putra Malaysia in 2007 majoring in Biomedical Sciences (First class) and obtained his doctoral degree from the University of Oxford (UK) in 2011 with his study in Cardiosphere-derived stem cells and regenerative medicine.

He was also a Visiting Research Fellow in King’s College London in 2014 and a postdoctoral research fellow at Massachusetts General Hospital, Harvard Medical School (US) in 2016.

He was awarded the excellent service award in 2015 by Universiti Sains Malaysia and received the recognition for molecular medicine with the ‘Young Investigator Award’ twice (in 2013 and 2015); for his work in harnessing bone marrow mesenchymal stem cells for enhancing c-kit cardiac stem cell functions.

Dr. TAN is currently serving Universiti Sains Malaysia at Advanced Medical and Dental Institute in Kepala Batas, Penang, as a senior lecturer to continue his research venture on heart tissue engineering and regeneration using human-derived induced pluripotent stem cells. He is also looking into the concept of re-utilising the native extracellular matrix scaffold in organ from cadaveric donor as the blueprint with preserved architecture for homing cellular blocks to make engineering functional organ possible.

His current work focuses on derivation of proepicardial cells, sinoatrial-like pacemaker cells and ventricular cardiomyocytes from iPSCs to their potential in therapeutic applications.

Prof. WEI LI

DIRECTOR, EYE INSTITUTE of Xiamen University

M.D., M.SCI.

Biography:

Amniotic membrane related tissue engineering: Amniotic membrane has been widely applied in ophthalmology and other tissue engineering areas in the past 10 years due to its special biological properties and weak immunogenicity. In ophthalmology, amniotic membrane is mainly used in the treatment of ocular surface diseases. A large number of clinical studies have shown that amniotic membrane is meditative in anti-inflammation, anti-scarring, anti-angiogenesis, as well as the promotion of the ocular surface epithelial wound healing. Our team has a strong background in amniotic membrane research. Previously, we have investigated the therapeutic mechanism of amniotic membrane in the treatment of ocular surface diseases at molecular and cellular levels. We are now interested in new applications of amniotic membrane in different medical science areas, and the development of new tissue engineered products related to amniotic membrane.

Squamous Metaplasia of the Ocular Surface Epithelium: Squamous metaplasia of the ocular surface epithelium is frequently present in various ocular surface diseases such as dry eye, Stevens-Johnson syndrome, cicatricial pemphigoid, pterygium and pinguecula. Our team has set up a squamous metaplasia tissue culture model using air-liquid interface culture of corneal limbus or conjunctival tissue, and found that p38 MAPK and Wnt signalling pathway is involved in the pathogenesis of squamous metaplasia. We also found down-regulation or silence of pax6 gene is associated with abnormal epidermal differentiation of the ocular surface epithelium. We further found that application of p38 MAPK inhibitor, re-introducing of pax6 gene, co-culture with amniotic membrane, application of amniotic membrane extract, and low oxygen tension culture environment can inhibit or reverse squamous metaplasia of ocular surface epithelium to a certain degree in ex vivo tissue culture model. We now have great interest in the clinic treatment of squamous metaplasia based on our new knowledge on this pathological process.

DR. CHUA KOK SENG

ANAESTHESIOLOGY & CRITICAL CARE, Gleneagles Kuala Lumpur

MBBS (MALAYA), DA (UK), FFARCS (IRELAND)

Biography:

Dr Chua Kok Seng has been involved in the Science of Stem Cell Biology and Therapeutics since 2000. In 2006, he was invited to be a board member of Stem Cell Berhad, a company listed on Bursa Malaysia. He has since been involved in developing stem cell therapeutics in the fields of Orthopaedics, Cardiology, and Neurology. Over the past 18 years, he has served as a treating physician for numerous stem cell companies in Malaysia and has been invited to speak at meetings and conferences. Since 2018, he has conducted clinical research on the use of Exosomes from Mesenchymal Stem Cells as a means of treatment in regenerative medicine.

Dr Chua’s area of interest in regenerative medicine includes;

Neurology: Autism, Neurodegenerative disease, Traumatic Brain Injury, Hypoxia, Ischemic Encephalitis, and Cerebral palsy”

Orthopaedics: Trauma medicine, Spinal Cord Injuries and Neuropathic Pain, Joint Arthropathy (Degenerative Traumatic, and Autoimmune)

Cardiology: Chronic Heart Failure

Autoimmune disease: Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), and Rheumatoid Arthritis), and General Wellness and Anti-Aging Medicine